MUDDY/insights

← Case indexEROS

Eros International / Eros STX Global (NYSE: EROS, formerly)

Kerrisdale's November 2015 short, the 2020 merger with STX Entertainment, and the 2022 separation that effectively ended the listed parent.

Eros International corporate logo
Eros International — Bollywood film distributionLogo via Wikimedia Commons
Key FactDetail
ReportForensic Short — Closed Case
Publication dateMay 15, 2022
IssuerEros International Plc (historical NYSE-listed Bollywood film distributor); successor Eros STX Global Corporation (post-July 2020 merger); STX Entertainment subsequently separated to Najafi Companies (2022)
TickerNYSE: EROS (historical, delisted)
Original shortKerrisdale Capital — "Eros International: Bollywood Smoke and Mirrors" (November 2015)
Headline post-publication eventsMulti-year share-price decline; merger with STX Entertainment to form Eros STX Global Corporation (closed July 30, 2020); subsidiary FSO Jones Chapter 11 (February 28, 2022); other STX subsidiary bankruptcies; Najafi Companies acquisition of STX from Eros STX (closed 2022)
RatingSHORT — Closed Case (original listed parent wound down)

Why We Are Publishing Today

The Eros International file is one of the more-protracted forensic-short outcomes in the modern catalogue. The original November 2015 short publication on the NYSE-listed Bollywood film distributor alleged misrepresentation of underlying revenue and operating substance. Five years later, Eros pursued a strategic-acquirer-style merger with STX Entertainment to form Eros STX Global Corporation, which itself fragmented across 2022 — subsidiary Chapter 11 filings on certain film-rights-holding entities, and the separation of STX to The Najafi Companies. The case is, in this respect, a long-arc closure of the original thesis through multiple corporate-action stages rather than through a clean enforcement outcome.

This Closed Case write-up consolidates the public record from the original short publication through the 2022 separation.


Section 1 — The Thesis (As Of November 2015)

Our reading of Eros, at the time the issuer was first publicly questioned, identified three core deficiencies:

  • Revenue from Indian film distribution and ancillary content licensing that materially exceeded the cash collections the operating business could generate;
  • Related-party arrangements with affiliated content-licensing counterparties in ways that did not reflect arms-length terms;
  • Receivables disclosures that aged in a manner inconsistent with arms-length commercial-counterparty cash conversion.

Eros rejected the allegations comprehensively.

Section 2 — Multi-Year Share-Price Decline (2015–2019)

The post-publication share-price path was characteristic of contested-posture forensic-short cases:

  • 2015–2017. Sequential share-price decline punctuated by issuer responses and disclosure updates;
  • 2018–2019. Continued operating-margin and receivables-quality pressure; auditor changes;
  • Early 2020. Pre-merger negotiations with STX Entertainment.

Section 3 — The 2020 STX Merger and the 2022 Separation

In April 2020, Eros International and STX Entertainment entered into a definitive merger agreement. The transaction closed on July 30, 2020, forming Eros STX Global Corporation. The combined entity briefly traded on the NYSE.

Through 2022, the Eros STX structure fragmented:

  • February 28, 2022. FSO Jones, an Eros STX subsidiary holding rights to the Greenland: Migration film, filed for Chapter 11.
  • 2022. Another Eros STX subsidiary holding rights to The Contractor (a Chris Pine / Ben Foster thriller) was placed into Chapter 11.
  • April 2022. The Najafi Companies acquired STX Entertainment from Eros STX Global Corporation, with Birch Grove LP and 777 Partners providing financing. The transaction effectively separated STX from Eros and ended the merged Eros STX structure as an integrated entity.

Section 4 — Where Things Stand And What We Take From The Case

As of this writing:

  • The original Eros International NYSE listing structure is wound down;
  • STX Entertainment continues to operate as an independent studio under Najafi Companies ownership;
  • The residual Eros operating business and the wind-down of the Eros STX listed structure are substantially complete.

What we take from the Eros case:

  1. Long-arc closures via corporate-action stages are common in contested-posture cases. Where an issuer initially contests, the resolution path often runs through multiple corporate-action stages (merger, subsidiary bankruptcies, separation transactions) over years rather than through a single clean enforcement outcome.
  2. Strategic-merger restructurings can be a partial closure mechanism. The 2020 Eros / STX merger represented a partial substantive response — combining a disputed cash-flow-quality issuer with an operating studio acquirer — even though the integrated combined entity itself did not durably succeed.
  3. The post-merger separation pattern is instructive. The 2022 Najafi acquisition of STX effectively recovered the operating-studio asset for an unrelated buyer, while the Eros-side residual structure wound down separately. The pattern of separation rather than integration outcomes in contested-posture mergers is a recurring 2010s and 2020s structure that warrants comparative analysis in subsequent cases.

Source Index (selected)

  • Eros International Plc — Form 20-F filings, 2015–2019 (SEC EDGAR).
  • Eros International Plc / STX Entertainment — merger documentation, April–July 2020; closing announcement July 30, 2020.
  • Chapter 11 filings — FSO Jones (Eros STX subsidiary), February 28, 2022; other STX subsidiary bankruptcies, 2022.
  • The Najafi Companies — STX Entertainment acquisition documentation, 2022.

— Muddy Insights, May 15, 2022.

// More files

  1. 028CURR · 2026-10-21Currenc Group Inc. (NASDAQ: CURR) — Forensic FileA Charging Order Over The Only Asset That Matters. The Same 100,465 Tranglo Shares Sold For US$400M Are Now Charged To A Judgment Creditor.NOT RATED — Forensic File
  2. 027DLXY · 2026-07-21Delixy Holdings Ltd. (NASDAQ: DLXY) — Forensic Short ReportThe IPO Funded An Exit, Not An Expansion. Dividends Out 4x What The Public Put In.NOT RATED — Research case study
  3. 026TROO · 2026-07-15TROOPS, Inc. (NASDAQ: TROO) — Forensic Short UpdateThe August 20 Endgame: Winding-Up Exposure, Suspension Mechanics, And A Support Bid Running On FumesSHORT — High conviction
  4. 025ADANIENT · 2026-05-15Adani Enterprises (NSE: ADANIENT)Three years after Hindenburg, two years after OCCRP, eighteen months after the EDNY indictment — what the public record now shows.SHORT — Update
  5. 024TROO · 2026-05-05TROOPS, Inc. (NASDAQ: TROO) — Forensic Short UpdateAuditor Replaced. Lock-Up Eased. Annual Report Past Due.SHORT — High conviction
  6. 023TRE · 2026-04-15Sino-Forest Corporation (TSX: TRE)The founding case of the modern China-short genre — fifteen years on.SHORT — Closed Case
  7. 022BUR · 2026-03-30Burford Capital (NYSE/LSE: BUR)Six years on from Muddy Waters' mismarking thesis — what the Second Circuit's March 2026 reversal of the YPF judgment changes.NEUTRAL
  8. 021IEP · 2026-02-25Icahn Enterprises L.P. (NASDAQ: IEP)Three years after Hindenburg's "Pied Piper of Pumpland" — distributions, the SEC settlement, and the margin-loan unwind.SHORT — Update
  9. 020WDI · 2026-02-01Wirecard AG (XETRA: WDI) — Closed-Case RetrospectiveSix years after the €1.9B missing cash — what a streamlined trial, a €140M civil award, and the Marsalek-as-FSB-asset disclosures now confirm.SHORT — Closed Case
  10. 019NKLA · 2026-01-15Nikola Corporation (NASDAQ: NKLA)The Hindenburg short, the Milton conviction, the Trump pardon, and the company's own Chapter 11.SHORT — Closed Case
  11. 018MAGH · 2025-12-02Magnitude International Ltd. (NASDAQ: MAGH) — Forensic ShortPenny-Priced Pre-IPO Equity, Eight-Month Cashout, Resale Shelf Engineered for Insider Exit.SHORT — High conviction
  12. 017VRX · 2025-10-21Valeant Pharmaceuticals (NYSE: VRX, now Bausch Health: BHC)Citron's "Pharmaceutical Enron" call, the Philidor disclosure, and the ten-year recovery that never came.SHORT — Closed Case
  13. 016TIO · 2025-09-01Tingo Group (NASDAQ: TIO)Hindenburg's June 2023 short, SEC fraud charges, the $250M civil judgment, and the founder still at large.SHORT — Closed Case
  14. 015EBIX · 2024-09-15Ebix, Inc. (NASDAQ: EBIX)Hindenburg's June 2021 short, the December 2023 Chapter 11, the $400M Zinnia sale, and the August 2024 emergence under Eraaya LifeSpaces sponsorship.SHORT — Update
  15. 014FFGRP · 2024-07-15Folli Follie (ATHEX: FFGRP)QCM's May 2018 short, the largest stock-market fraud in modern Greek history, and the June 2024 prison sentences.SHORT — Closed Case
  16. 013SNH · 2024-04-15Steinhoff International (JSE: SNH)Viceroy's December 2017 short, €7B+ of confirmed accounting irregularities, and the July 2023 vote to dissolve.SHORT — Closed Case
  17. 012RIDE · 2024-04-01Lordstown Motors (NASDAQ: RIDE, now Nu Ride: NRDE)From SPAC pre-orders to Chapter 11 to a litigation-vehicle reorganization.SHORT — Closed Case
  18. 011GSX · 2022-09-15GSX Techedu (NYSE: GSX, now Gaotu: GOTU)Muddy Waters' May 2020 short, the July 2021 "double reduction" policy that vindicated the broader sector thesis, and the 2022 HFCAA delisting.SHORT — Closed Case
  19. 010QPP · 2021-09-15Quindell PLC (LSE AIM: QPP, now Watchstone)Gotham City Research's April 2014 short, the £637M Slater & Gordon sale, the £11M settlement that followed, and the SFO investigation that ended without charge.SHORT — Closed Case
  20. 009SONG · 2020-10-15Akazoo S.A. (NASDAQ: SONG)QCM's April 2020 short, SEC fraud charges, and the fastest US-regulator resolution of a SPAC-era fraud.SHORT — Closed Case
  21. 008INSY · 2020-02-15Insys Therapeutics (NASDAQ: INSY)Citron's August 2016 short, the Subsys opioid-marketing prosecution, the June 2019 bankruptcy, and the first US pharmaceutical-executive RICO conviction for opioid marketing.SHORT — Closed Case
  22. 007ON · 2020-01-15Bio-on S.p.A. (Borsa Italiana AIM: ON) — Forensic Short Closed CaseAuditor-quality bioplastics revenue, a same-quarter founder arrest, and the fastest closure of any modern European forensic-short case.SHORT — Closed Case
  23. 006N21 · 2019-01-15Noble Group (SGX: N21)Iceberg Research's February 2015 short, multi-year mark-to-model contestation, and the 2018 break-up of one of Asia's largest commodity traders.SHORT — Closed Case
  24. 005NQ · 2018-01-15NQ Mobile (NYSE: NQ)Muddy Waters' October 2013 short, four years of contested public posture, and the eventual NYSE delisting in 2017.SHORT — Closed Case
  25. 004FMCN · 2015-09-15Focus Media (NASDAQ: FMCN, formerly)Muddy Waters' November 2011 short, the 2013 take-private at a premium, and the 2015 China A-share relisting at a multiple of the take-private price.SHORT — Counter-Case
  26. 003GOW · 2014-08-01Let's Gowex (BME MAB: GOW)Gotham City Research's July 2014 short, the CEO confession within days, and the fastest forensic-short to bankruptcy in the modern catalogue.SHORT — Closed Case
  27. 002CCME · 2013-12-15China MediaExpress Holdings (NASDAQ: CCME)Muddy Waters' February 2011 short, auditor Deloitte's resignation, and the SEC fraud charges that followed.SHORT — Closed Case
  28. 001LFT · 2013-12-15Longtop Financial Technologies (NYSE: LFT)Citron's April 2011 short, Deloitte's May 2011 resignation letter, and the SEC's signature fraud case of the 2011 China-short wave.SHORT — Closed Case